ANALYSIS: Mistaken information, deep fakes, and deceitful, orchestrated campaigns have destroyed trust in governments and media – but business can also be its target.
Some brickbats and bouquets for whatever it is that happened in 2023.
ANALYSIS: Kiwi company helmed by London-based Texan will be stretching to beat bigger rivals, but has new clarity of purpose.
ANALYSIS: The US requires portfolio managers disclose how personally invested they are in their own funds – it’s time New Zealand did the same.
ANALYSIS: Margins are tighter, even though banks have higher interest rates on their side.
ANALYSIS: Industry wants a national bed tax – but will it be in place fast enough to deal with surging returning tourists?
ANALYSIS: How uncovering the identity of Bitcoin inventor Satoshi Nakamoto could be key for the fortunes of the Takapuna software company.
ANALYSIS: Should failed grocery startup have signed a pragmatic supply deal with supermarket duopoly until it got on its feet?
ANALYSIS: The craze for Ozempic may have contributed to ASX-listed CSL’s success having hiccups this year, but some analysts see a buying opportunity
ANALYSIS: NBR Listers’ pharma company cleared a major FDA hurdle last week but winning the US is far from assured.